New Delhi, Nov. 12 -- The National Pharmaceutical Pricing Authority (NPPA) has ordered strict nationwide monitoring to ensure patients benefit from recent price reductions on 137 non-scheduled anti-cancer drugs.

In an office memorandum issued on 11 November, the pricing regulator directed all state drug controllers (SDCs), state food and drug administrations (FDAs), and price monitoring and resource units (PMRUs) to enforce compliance with the trade margin rationalisation (TMR) framework. Notified via gazette notification on 17 October, the revised prices took effect from 9 November.

"SDCs shall submit an action taken report to NPPA by 16 November 2026," the memorandum stated.

Citing the latest revised price list submitted by pharmaceu...